Omniox Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Omniox Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014205
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Omniox Inc (Omniox) is a biotechnology company that develops new medicines for hypoxic diseases. The company’s H-NOX products are tailored for the treatment of hypoxic cancers, which include giloblastoma, metastatic brain cancer, head-and-neck cancer, pancreatic cancer, lung cancer, and prostate cancer in combination with standard of care radiation and chemotherapy. It provides engineering of unusually stable oxygen carrier technology to deliver oxygen into hypoxic tissues and improve the treatment of severe unmet medical needs. Its OMX-4.80P delivers oxygen into the tumor microenvironment. The company offers solutions for cure of impacts of cancer, cardiovascular diseases, trauma and other conditions. Omniox is headquartered in San Carlos, California, the US.

Omniox Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Omniox Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Omniox Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Omniox Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Omniox Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Omniox Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Omniox Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Omniox Raises USD4.7 Million in Venture Financing 10
Omniox Raises USD6.6 Million in Venture Financing 11
Omniox Raises US$3 Million In Venture Financing 12
Omniox Raises US$1 Million In Venture Financing 13
Omniox Inc – Key Competitors 14
Omniox Inc – Key Employees 15
Omniox Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Clinical Trials 17
Nov 17, 2016: Omniox presents preclinical data on immuno-sensitizing effects of OMX-4.80P in orthotopic glioblastoma tumors at the CNS Anti-Cancer Drug Discovery Conference and 21st Annual Society for Neuro-Oncology Meeting in Scottsdale, Arizona 17
Sep 26, 2016: Omniox presents preclinical data on OMX-4.80P’s immunostimulatory effects in hypoxic tumors at the CTI-CIMT-EATI-AACR 2nd International Cancer Immunotherapy Conference in New York, NY 18
Apr 20, 2016: Omniox presents preclinical data on OMX-4.80P as a cancer immunotherapy at the 2016 Annual Meeting of the American Association for Cancer Research in New Orleans, LA 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Omniox Inc, Pharmaceuticals & Healthcare, Key Facts 2
Omniox Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Omniox Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Omniox Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Omniox Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Omniox Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Omniox Raises USD4.7 Million in Venture Financing 10
Omniox Raises USD6.6 Million in Venture Financing 11
Omniox Raises US$3 Million In Venture Financing 12
Omniox Raises US$1 Million In Venture Financing 13
Omniox Inc, Key Competitors 14
Omniox Inc, Key Employees 15

★海外企業調査レポート[Omniox Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure life-threatening diseases. The company's pipeline products include SLN124, SLN500 and SLN360. Its SLN124 is developed for the treatment of cardiovascula …
  • New York Independent System Operator Inc:企業の戦略的SWOT分析
    New York Independent System Operator Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Camel-IDS NV-製薬・医療分野:企業M&A・提携分析
    Summary Camel-IDS NV (Camel-IDS) is a biotechnology company which develops targeted radionuclide therapeutic solutions for the treatment of cancer. The company focuses on developing its lead compound radiopharmaceutical drug for treatment of Her2 positive cancer. Its technology platform is based on …
  • 3M Company:企業のM&A・事業提携・投資動向
    3M Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 3M Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Electricity Authority of Cyprus:企業の戦略的SWOT分析
    Electricity Authority of Cyprus - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Brambles Limited (BXB):企業の財務・戦略的SWOT分析
    Brambles Limited (BXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Damas International Ltd:企業の戦略・SWOT・財務分析
    Damas International Ltd - Strategy, SWOT and Corporate Finance Report Summary Damas International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • All in West! Capital Corp:企業の戦略・SWOT・財務分析
    All in West! Capital Corp - Strategy, SWOT and Corporate Finance Report Summary All in West! Capital Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • EnviroMission Limited:電力:M&Aディール及び事業提携情報
    Summary EnviroMission Limited (EnviroMission) is a renewable energy company. It develops solar tower technology (STT). The company owns the license to STT across the world (excluding in China). EnviroMission’s STT uses solar radiation to heat air beneath a translucent canopy to create a solar therma …
  • Electra Private Equity PLC (ELTA):企業の財務・戦略的SWOT分析
    Electra Private Equity PLC (ELTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Citizen Watch Co., Ltd. (7762):企業の財務・戦略的SWOT分析
    Citizen Watch Co., Ltd. (7762) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Pakistan Oxygen Limited (LINDE):企業の財務・戦略的SWOT分析
    Pakistan Oxygen Limited (LINDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • BBB Technologies Inc:企業の製品パイプライン分析
    Summary BBB Technologies Inc (BBB Tech) is a development-stage medical technology company that develops medical devices and applications that facilitate the early diagnosis of metabolic and cardiovascular disorders. It discovers and develops single-drop and mobile integrated diagnostic tools for blo …
  • ONEOK Partners LP (OKS)-石油・ガス分野:企業M&A・提携分析
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …
  • Ultra Electronics Holdings plc:企業のM&A・事業提携・投資動向
    Ultra Electronics Holdings plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ultra Electronics Holdings plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Sientra Inc (SIEN):企業の財務・戦略的SWOT分析
    Summary Sientra Inc (Sientra) is a medical device company that manufactures and markets plastic surgery implantable devices. The company’s products comprise breast implants, breast tissue expanders, silicone scar treatment and additional tissue expanders. It offers reconstructive surgery devices suc …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lietuvos Draudimas AB:企業の戦略的SWOT分析
    Lietuvos Draudimas AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • PolyPid Ltd (POLY):製薬・医療:M&Aディール及び事業提携情報
    Summary PolyPid Ltd (PolyPid) is a pharmaceutical company that develops manufactures and commercializes therapies for the treatment of various medical conditions including infection, pain, inflammation and cancer. The company’s pipeline product candidates include D-Plex100, an antibiotic drug reserv …
  • Pharma Mar SA (PHM):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆